论文部分内容阅读
随着抗菌药物广泛用于幽门螺杆菌 (HelicobacterpyloriHp)感染 ,其耐药性问题日益突出。就全球而言 ,克拉霉素的耐药水平在 0 %～ 1 3 % ,且有逐年上升的趋势。Hp对克拉霉素的耐药性是由于 2 3SrRNA上点突变引起克拉霉素与核糖体结合力下降所致。甲硝唑的耐药水平在发展中国家和发达国家间存在显著差异 ;在女性中的耐药水平明显高于男性。Hp对甲硝唑的耐药性是由于rdxA基因上点突变引起Hp还原能力下降所致。Hp对其他抗生素耐药性的研究较少 ,其耐药水平也较低。目前 ,Hp耐药性是Hp治疗失败的主要原因 ,因此当前之急是探讨耐药机制、开发新药和研制疫苗
With the widespread use of antibacterials for Helicobacter pylori infection, the problem of drug resistance has become increasingly prominent. Globally, the level of resistance to clarithromycin is 0% ~ 13%, and there is a rising trend year by year. The resistance of Hp to clarithromycin is due to the decrease of the binding force between clarithromycin and ribosome caused by point mutation on 23SrRNA. The level of resistance to metronidazole is significantly different between developing and developed countries; the level of resistance among women is significantly higher than that of men. Hp resistance to metronidazole is due to point mutations in the rdxA gene caused by Hp reducing ability. Hp resistance to other antibiotics less research, its level of resistance is also low. Currently, Hp resistance is the main reason for the failure of Hp treatment, so the urgent need now is to explore drug resistance mechanisms, develop new drugs and develop vaccines